LUTETIUM (LU177) LILOTOMAB SATETRAXETAN

UNII:	054ZP16K2Q
Type:	INGREDIENT SUBSTANCE
Formula:
Preferred Substance Name:	LUTETIUM (LU177) LILOTOMAB SATETRAXETAN
GSRS Full Record:	054ZP16K2Q i

1453362-90-7
177LU-DOTA-HH1
177LU-TETRAXETAN-HH1
BETALUTIN
IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS CD37 (TSPAN26, TETRASPANIN-26)), MUS MUSCULUS MONOCLONAL ANTIBODY, LUTETIUM (LU 177) RADIOLABELLED SATETRAXETAN (DOTA DERIVATIVE) CONJUGATE
IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS CD37 (TSPAN26, TETRASPANIN-26)), MUS MUSCULUS MONOCLONAL ANTIBODY, LUTETIUM (LU 177) RADIOLABELLED SATETRAXETAN (DOTA DERIVATIVE) CONJUGATE; GAMMA1 HEAVY CHAIN (1-443) (MUS MUSCULUS VH (IGHV1S135*01 (96.90%)-(IGHD)-IGHJ4*01) (8.8.12) (1-119)-IGHG1*01 (CH1 E84>Q (177), P95>T (193), R96>W (194) (120-216), HINGE (217-229), CH2 (230-336), CH3 N84.2>D (395), N84.4>D (397) (337-441), CHS (442-443)) (120-443)), (221-214')-DISULFIDE WITH KAPPA LIGHT CHAIN (1'-214') (MUS MUSCULUS V-KAPPA (IGKV6-25*01 (93.70%)-IGKJ4*01) (6.3.9) (1'-107')-IGKC*01 (108'-214')); DIMER (223-223'':226-226'':228-228'')-TRISDISULFIDE, AN AVERAGE OF 1 TO 2 AMINO GROUPS (N6 OF LYSINES) ARE SUBSTITUTED: N-(RAC-(4-(((2R)-1,4,7,10-TETRAKIS(CARBOXYMETHYL)-1,4,7,10-TETRAAZACYCLODODECAN-2-YL)METHYL)PHENYL)CARBAMOTHIOYL) ( 177LU)LUTETIUM(3+) CHELATE
LILOTOMAB SATETRAXETAN LUTETIUM LU-177
LUTETIUM (177LU) LILOTOMAB SATETRAXETAN
LUTETIUM (LU177) LILOTOMAB SATETRAXETAN [USAN]
Lutetium (177Lu) lilotomab satetraxetan [WHO-DD]
lutetium (¹⁷⁷Lu) lilotomab satetraxetan [INN]

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

LUTETIUM (LU177) LILOTOMAB SATETRAXETAN

Synonyms and Mappings

Resources